ProQuad

BIOLOGICAL3 trials

Sponsors

Merck Sharp & Dohme LLC, GlaxoSmithKline, Medical University of South Carolina

Conditions

ChickenpoxHEART DISEASEHepatitis ALIVER FAILURE, ACUTEMeaslesMeasles-Mumps-RubellaMumpsRENAL INSUFFICIENCY, CHRONIC

Early Phase 1

Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant

CompletedNCT02687763

Medical University of South CarolinaHEART DISEASE, LIVER FAILURE, ACUTE, RENAL INSUFFICIENCY, CHRONIC

Start: 2015-12-31End: 2016-11-03Updated: 2019-02-12

Phase 3

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age

CompletedNCT01621802

GlaxoSmithKlineMeasles-Mumps-Rubella

Start: 2012-06-21End: 2015-11-09Updated: 2019-11-25

Phase 4

Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)

CompletedNCT00326183

Merck Sharp & Dohme LLCChickenpox, Hepatitis A, Measles +2

Start: 2007-03-26End: 2008-01-15Updated: 2019-02-04

Related Papers

A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration

Human Vaccines & Immunotherapeutics2019-02-2014 citations